

CERTIFICATE OF ANALYSIS No.: 2024-15664

CLIENT

Pharmahemp d.o.o., Cesta v Gorice 8
1000 Ljubljana, Slovenija



SAMPLE *

COSMO HEMP'S CBD ELIXIR TOOTHPASTE

Sample condition: SUITABLE

Work order: 2024-112478

Sample received: 03/12/2024

Sample ID: 2449026

Analysis ID: 2024_395

Start of analysis: 03/12/2024

Sample type: Paste

Method ID: PHL_RPC_16C

End of analysis: 04/12/2024

















Batch No.: * KOO000069

Method SOP: MET-LAB-001-08

Analyst: Valentina Malin

* Information provided by the client.

CANNABINOID TRACE ANALYSIS

		Concentration [% w/w]	Expanded uncertainty [% w/w]	LOQ [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV	- Cannabidivarin	0.0117	0.0027	0.00300	
CBDA	- Cannabidiolic acid	< LOQ	n/a	0.00300	
CBGA	- Cannabigerolic acid	< LOQ	n/a	0.00300	
CBG	- Cannabigerol	< LOQ	n/a	0.00300	
CBD	- Cannabidiol	0.076	0.015	0.00300	
THCV	- Tetrahydrocannabivarin	< LOQ	n/a	0.00300	
CBN	- Cannabinol	< LOQ	n/a	0.00300	
Δ⁹-THC	- Δ-9-Tetrahydrocannabinol	< LOQ	n/a	0.00300	
Δ⁸-THC	- Δ-8-Tetrahydrocannabinol	< LOQ	n/a	0.00300	
CBL	- Cannabicyclol	< LOQ	n/a	0.00300	
CBC	- Cannabichromene	< LOQ	n/a	0.00300	
Δ⁹-THCA	- Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	0.00300	
CBV	- Cannabivarin	< LOQ	n/a	0.00300	
CBCA	- Cannabichromenic acid	< LOQ	n/a	0.00300	
CBT	- Cannabicitran	< LOQ	n/a	0.00300	
CBE	- Cannabielsoin	< LOQ	n/a	0.00300	

Units and abbreviations: % w/w = weight percent, LOQ = the limit of quantitation, ND = not detected, n/a = not available.

The results given herein apply only to the sample as received and tested. Expanded Uncertainty was calculated using coverage factor $k = 2$, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.